IGC Pharma Inc Stock Price, News & Analysis

India Globalization Capital reported Q3 results for the fiscal year 2022. The Company appointed James Moran to its Board of Directors, enhancing its expertise in healthcare. It completed a Phase 1 clinical trial for IGC-AD1, aimed at treating Alzheimer’s disease, showing promising results in reducing Neuropsychiatric Symptoms. The Life Sciences segment generated $134 thousand in revenue, while the Infrastructure segment brought in $8 thousand. The net loss was approximately $2.38 million, or ($0.05) per share. R&D expenses rose to $377 thousand, reflecting increased clinical trial activities.

India Globalization Capital, Inc. (IGC) has appointed former Congressman Jim Moran as an independent Director on its Board. With 24 years in Congress, Moran is known for his bipartisan leadership and focus on healthcare, environment, and defense. He will provide valuable insights as IGC advances its Phase 2/3 trials of the THC-based investigational drug for Alzheimer’s disease. Moran's experience in innovative research could strengthen IGC’s initiatives in cannabinoid-based therapies, aiming for FDA-approved clinical trials.

India Globalization Capital (IGC) announced positive results from its Phase 1 clinical trial for IGC-AD1, a cannabinoid-based drug for Alzheimer's disease. The primary endpoint focused on safety and tolerability was successfully met, with minimal adverse events reported. The trial involved 36 elderly patients who showed no serious safety concerns. The company plans to advance the trial to assess efficacy, pending FDA approval. IGC aims to improve the quality of life for Alzheimer's patients through further testing of IGC-AD1.

India Globalization Capital, Inc. (IGC) has announced preliminary results from its Phase 1 clinical trial for IGC-AD1, a cannabis-based drug candidate for Alzheimer’s disease. Key insights into pharmacokinetics and genotyping have been obtained, crucial for determining optimal dosing in future trials pending FDA approval. The trial showed mean T_max values of 2.15 hours for THC and 1.9 hours for OH-THC, and mean T_1/2 values of 3.60 hours for THC and 3.30 hours for OH-THC, suggesting safe dosing frequencies. Further trials are planned to establish the drug's safety and efficacy.

India Globalization Capital, Inc. (IGC) announced preliminary positive findings from its Phase 1 clinical trial for IGC-AD1, a THC-based drug aimed at treating Alzheimer’s symptoms. The trial highlighted significant decreases in anxiety (50-60%) and agitation (35-60%) among participants. The results were shared in a Clinical/Statistical Report filed with the FDA. IGC plans to expand the study with a placebo-controlled trial pending FDA approval. Alzheimer's affects 50 million globally, with no approved medications for symptom relief, underscoring the potential impact of IGC-AD1.

India Globalization Capital, Inc. (NYSE American: IGC) reported financial results for Q2 of fiscal 2022, ending September 30, 2021. Revenue declined to approximately $56,000 from $125,000 in the same quarter last year, with Infrastructure segment revenue at $3,000 down from $67,000. SG&A expenses surged to about $4.1 million due to inventory theft and legal costs. R&D expenses increased slightly to $276,000 and the net loss widened to approximately $4.3 million or ($0.08) per share. The company is progressing with the Phase 1 trial of its THC-based drug IGC-AD1 for Alzheimer’s, expecting future FDA submissions.

India Globalization Capital, Inc. (IGC) held its Annual Meeting of Shareholders on October 15, 2021, where all voting matters in the Definitive Proxy filed with the SEC were approved.

Key approvals included:

• Election of Richard Prins to the board until 2024.
• Ratification of Manohar Chowdhry & Associates as the independent accounting firm for fiscal year 2022.
• Granting 3,500,000 shares to employees and consultants based on performance metrics.
• Proposal to adjourn the meeting if necessary to solicit more proxy votes.

India Globalization Capital (IGC) has completed its Phase 1 clinical trial of IGC-AD1, a cannabis-based investigational drug for Alzheimer’s disease. The trial involved 12 participants, primarily elderly individuals with mild to moderate Alzheimer’s. Results indicate that IGC-AD1 was safe and well-tolerated. Secondary endpoints have also been completed, but results are yet to be disclosed. IGC plans to seek FDA concurrence on these findings and aims for future trials to support potential relief for the projected 50 million Alzheimer’s patients worldwide by 2030.

India Globalization Capital, Inc. (IGC) reported financial results for Q2 2021, revealing revenues of approximately $77,000, down from $584,000 in Q2 2020. The decline is attributed to COVID-19's impact, particularly in its Infrastructure segment. Notably, IGC received a patent for its Alzheimer’s treatment, IGC-AD1, and completed its Phase 1 clinical trial. R&D expenses rose to about $444,000 due to the trial, while the company recorded a net loss of $1.8 million, slightly improved from $1.9 million a year earlier. Liquidity remains adequate for upcoming efficacy trials.